SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Paula K. Schweitzer, Principles and Practice of Sleep Medicine, 2011,

    CrossRef

  2. 2
    Paula K. Schweitzer, Allergy/Respiratory and Cardiovascular Drugs, Sleep Medicine Clinics, 2010, 5, 4, 541

    CrossRef

  3. 3
    Ho-Won Lee, Hae Won Lee, Dae Jin Park, Sung Ok Moon, Ju Hee Ahn, Mi Jin Kim, Sung-Doo Kim, Ji-Eun Kim, Young-Ran Yoon, The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers, Expert Opinion on Pharmacotherapy, 2008, 9, 10, 1655

    CrossRef

  4. 4
    Paula K. Schweitzer, Principles and Practice of Sleep Medicine, 2005,

    CrossRef

  5. 5
    I. Hindmarch, CNS effects of antihistamines: is there a third generation of non-sedative drugs?, Clinical & Experimental Allergy Reviews, 2002, 2, 1
  6. 6
    Garry M Walsh, Emerging safety issues regarding long-term usage of H1-receptor antagonists, Expert Opinion on Drug Safety, 2002, 1, 3, 225

    CrossRef

  7. 7
    J. M. Gandon, H. Allain, Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers, British Journal of Clinical Pharmacology, 2002, 54, 1
  8. 8
    Jim Stevenson, Deborah Cornah, Philippe Evrard, Valere Vanderheyden, Catherine Billard, Martin Bax, Anne Van Hout, Long-Term Evaluation of the Impact of the H1-Receptor Antagonist Cetirizine on the Behavioral, Cognitive, and Psychomotor Development of Very Young Children with Atopic Dermatitis, Pediatric Research, 2002, 52, 2, 251

    CrossRef

  9. 9
    Julie C. Qidwai, Ginger S. Watson, John M. Weiler, Sedation, cognition, and antihistamines, Current Allergy and Asthma Reports, 2002, 2, 3, 216

    CrossRef

  10. 10
    I. Hindmarch, Z. Shamsi, The Effects of Single and Repeated Administration of Ebastine on Cognition and Psychomotor Performance in Comparison to Triprolidine and Placebo in Healthy Volunteers, Current Medical Research and Opinion, 2001, 17, 4, 273

    CrossRef

  11. 11
    P. Van Cauwenberge, C. Bachert , G. Passalacqua , J. Bousquet , G. W. Canonica , S. R. Durham , W. J. Fokkens , P. H. Howarth , V. Lund , H.-J. Malling , N. Mygind , D. Passali , G. K. Scadding , D.-Y. Wang , Consensus statement on the treatment of allergic rhinitis, Allergy, 2000, 55, 2
  12. 12
    Z Shamsi, I Hindmarch, Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios, Human Psychopharmacology: Clinical and Experimental, 2000, 15, S1
  13. 13
    I. Hindmarch, Z. Shamsi, Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects, Clinical & Experimental Allergy, 1999, 29, S3
  14. 14
    G. K. Scadding, Clinical assessment of antihistamines in rhinitis, Clinical & Experimental Allergy, 1999, 29, S3
  15. 15
    W. W. Busse, K. A. Mcgill, R. J. Horwitz, Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease, Clinical & Experimental Allergy, 1999, 29,
  16. 16
    J. Spaeth, L. Klimek, R. Mösges, Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment, Allergy, 1996, 51, 12
  17. 17
    G. Passalacqua, J. Bousquet, C. Bachert, M. K. Church, C. Bindslev-Jensen, L. Nagy, P. Szemere, R. J. Davies, S. R. Durham, F. Horak, K. Kontou-Fili, H.-J. Malling, P. Cauwenberge, G. W. Canonica, The clinical safety of H1-receptor antagonists: An EAACI position paper, Allergy, 1996, 51, 10, 666

    CrossRef

  18. You have free access to this content18
    G. Passalacqua, J. Bousquet, C. Bachert, M. K. Church, C. Bindslev-Jensen, L. Nagy, P. Szemere, R. J. Davies, S. R. Durham, F. Horak, K. Kontou-Fili, H.-J. Malling, P. Cauwenberge, G. W. Canonica, The clinical safety of H1-receptor antagonists: An EAACI position paper, Allergy, 1996, 51, 10
  19. 19
    Andrew Crowe, Case Studies of Non-CNS Drugs to Minimize Brain Penetration—Nonsedative Antihistamines,